Literature DB >> 33546502

The Tumor Microenvironment in Liver Metastases from Colorectal Carcinoma in the Context of the Histologic Growth Patterns.

Gemma Garcia-Vicién1,2, Artur Mezheyeuski3, María Bañuls1,2, Núria Ruiz-Roig1,4, David G Molleví1,2.   

Abstract

Colorectal carcinoma (CRC) is the third most common cancer. Likewise, it is a disease that has a long survival if it is prematurely detected. However, more than 50% of patients will develop metastases, mainly in the liver (LM-CRC), throughout the evolution of their disease, which accounts for most CRC-related deaths. Treatment it is certainly a controversial issue, since it has not been shown to increase overall survival in the adjuvant setting, although it does improve disease free survival (DFS). Moreover, current chemotherapy combinations are administered based on data extrapolated from primary tumors (PT), not considering that LM-CRC present a very particular tumor microenvironment that can radically condition the effectiveness of treatments designed for a PT. The liver has a particular histology and microenvironment that can determine tumor growth and response to treatments: double blood supply, vascularization through fenestrated sinusoids and the presence of different mesenchymal cell types, among other particularities. Likewise, the liver presents a peculiar immune response against tumor cells, a fact that correlates with the poor response to immunotherapy. All these aspects will be addressed in this review, putting them in the context of the histological growth patterns of LM-CRC, a particular pathologic feature with both prognostic and predictive repercussions.

Entities:  

Keywords:  capsule; carcinoma-associated fibroblasts; desmoplasia; hepatic stellate cells; histologic growth patterns; liver; microenvironment

Mesh:

Substances:

Year:  2021        PMID: 33546502      PMCID: PMC7913731          DOI: 10.3390/ijms22041544

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  106 in total

Review 1.  Environment-mediated drug resistance: a major contributor to minimal residual disease.

Authors:  Mark B Meads; Robert A Gatenby; William S Dalton
Journal:  Nat Rev Cancer       Date:  2009-08-20       Impact factor: 60.716

2.  Functional heterogeneity of cancer-associated fibroblasts from human colon tumors shows specific prognostic gene expression signature.

Authors:  Mercedes Herrera; Abul B M M K Islam; Alberto Herrera; Paloma Martín; Vanesa García; Javier Silva; Jose M Garcia; Clara Salas; Ignacio Casal; Antonio García de Herreros; Félix Bonilla; Cristina Peña
Journal:  Clin Cancer Res       Date:  2013-09-19       Impact factor: 12.531

3.  Increased Infiltration of Natural Killer and T Cells in Colorectal Liver Metastases Improves Patient Overall Survival.

Authors:  Matteo Donadon; Kelly Hudspeth; Matteo Cimino; Luca Di Tommaso; Max Preti; Paolo Tentorio; Massimo Roncalli; Domenico Mavilio; Guido Torzilli
Journal:  J Gastrointest Surg       Date:  2017-05-23       Impact factor: 3.452

4.  Prognosis according to histochemical analysis of liver metastases removed at liver resection.

Authors:  S M Brunner; R Kesselring; C Rubner; M Martin; T Jeiter; T Boerner; P Ruemmele; H J Schlitt; S Fichtner-Feigl
Journal:  Br J Surg       Date:  2014-10-21       Impact factor: 6.939

5.  Proangiogenic role of tumor-activated hepatic stellate cells in experimental melanoma metastasis.

Authors:  Elvira Olaso; Clarisa Salado; Eider Egilegor; Virginia Gutierrez; Aitor Santisteban; Pau Sancho-Bru; Scott L Friedman; Fernando Vidal-Vanaclocha
Journal:  Hepatology       Date:  2003-03       Impact factor: 17.425

6.  Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854).

Authors:  T J A Dekker; C J H van de Velde; G W van Pelt; J R Kroep; J-P Julien; V T H B M Smit; R A E M Tollenaar; W E Mesker
Journal:  Breast Cancer Res Treat       Date:  2013-05-25       Impact factor: 4.872

7.  Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer.

Authors:  Ana Costa; Yann Kieffer; Alix Scholer-Dahirel; Floriane Pelon; Brigitte Bourachot; Melissa Cardon; Philemon Sirven; Ilaria Magagna; Laetitia Fuhrmann; Charles Bernard; Claire Bonneau; Maria Kondratova; Inna Kuperstein; Andrei Zinovyev; Anne-Marie Givel; Maria-Carla Parrini; Vassili Soumelis; Anne Vincent-Salomon; Fatima Mechta-Grigoriou
Journal:  Cancer Cell       Date:  2018-02-15       Impact factor: 31.743

8.  MIF, secreted by human hepatic sinusoidal endothelial cells, promotes chemotaxis and outgrowth of colorectal cancer in liver prometastasis.

Authors:  Chun-Ting Hu; Li-Li Guo; Na Feng; Lei Zhang; Na Zhou; Li-Li Ma; Lan Shen; Gui-Hui Tong; Qian-Wen Yan; Shi-Jie Zhu; Xiu-Wu Bian; Mao D Lai; Yong-Jian Deng; Yan-Qing Ding
Journal:  Oncotarget       Date:  2015-09-08

9.  Thy-1+ Cancer-associated Fibroblasts Adversely Impact Lung Cancer Prognosis.

Authors:  Mark J Schliekelman; Chad J Creighton; Brandi N Baird; Yulong Chen; Priyam Banerjee; Neus Bota-Rabassedas; Young-Ho Ahn; Jonathon D Roybal; Fengju Chen; Yiqun Zhang; Dhruva K Mishra; Min P Kim; Xin Liu; Barbara Mino; Pamela Villalobos; Jaime Rodriguez-Canales; Carmen Behrens; Ignacio I Wistuba; Samir M Hanash; Jonathan M Kurie
Journal:  Sci Rep       Date:  2017-07-25       Impact factor: 4.379

10.  Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma.

Authors:  Jeffrey J Wallin; Johanna C Bendell; Roel Funke; Mario Sznol; Konstanty Korski; Suzanne Jones; Genevive Hernandez; James Mier; Xian He; F Stephen Hodi; Mitchell Denker; Vincent Leveque; Marta Cañamero; Galina Babitski; Hartmut Koeppen; James Ziai; Neeraj Sharma; Fabien Gaire; Daniel S Chen; Daniel Waterkamp; Priti S Hegde; David F McDermott
Journal:  Nat Commun       Date:  2016-08-30       Impact factor: 14.919

View more
  5 in total

Review 1.  Histopathological growth patterns of liver metastasis: updated consensus guidelines for pattern scoring, perspectives and recent mechanistic insights.

Authors:  Emily Latacz; Diederik Höppener; Ali Bohlok; Vincent Donckier; Peter M Siegel; Raymond Barnhill; Marco Gerling; Cornelis Verhoef; Peter B Vermeulen; Sophia Leduc; Sébastien Tabariès; Carlos Fernández Moro; Claire Lugassy; Hanna Nyström; Béla Bozóky; Giuseppe Floris; Natalie Geyer; Pnina Brodt; Laura Llado; Laura Van Mileghem; Maxim De Schepper; Ali W Majeed; Anthoula Lazaris; Piet Dirix; Qianni Zhang; Stéphanie K Petrillo; Sophie Vankerckhove; Ines Joye; Yannick Meyer; Alexander Gregorieff; Nuria Ruiz Roig; Fernando Vidal-Vanaclocha; Larsimont Denis; Rui Caetano Oliveira; Peter Metrakos; Dirk J Grünhagen; Iris D Nagtegaal; David G Mollevi; William R Jarnagin; Michael I D'Angelica; Andrew R Reynolds; Michail Doukas; Christine Desmedt; Luc Dirix
Journal:  Br J Cancer       Date:  2022-06-01       Impact factor: 9.075

2.  miR-204-5p in vivo inhibition cause diminished CD45RO cells rate in lungs of melanoma B16-bearing mice.

Authors:  Nadezhda Palkina; Mariya Aksenenko; Danil Zemtsov; Semyon Lavrentev; Ivan Zinchenko; Vasiliy Belenyuk; Andrey Kirichenko; Andrey Savchenko; Tatiana Ruksha
Journal:  Noncoding RNA Res       Date:  2022-06-03

3.  Development and validation of genomic and epigenomic signatures associated with tumor immune microenvironment in hepatoblastoma.

Authors:  Yanbing Zhang; Tian Zhang; Qiang Yin; Haiyan Luo
Journal:  BMC Cancer       Date:  2021-10-29       Impact factor: 4.430

Review 4.  Clinical implications and mechanism of histopathological growth pattern in colorectal cancer liver metastases.

Authors:  Bing-Tan Kong; Qing-Sheng Fan; Xiao-Min Wang; Qing Zhang; Gan-Lin Zhang
Journal:  World J Gastroenterol       Date:  2022-07-14       Impact factor: 5.374

Review 5.  Liver Immune Microenvironment and Metastasis from Colorectal Cancer-Pathogenesis and Therapeutic Perspectives.

Authors:  Xuezhen Zeng; Simon E Ward; Jingying Zhou; Alfred S L Cheng
Journal:  Cancers (Basel)       Date:  2021-05-17       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.